AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-28. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
== Education == The OECD's Programme for International Student Assessment (PISA) 2015: Thailand ranked 54th of 70 nations (1=best; 70=worst) in the triennial testing of 15 year-olds. Thai scores dropped in all subjects since the 2012 assessment. By subject, Thailand ranked 54th in math, 57th in reading, and 54th in science.
II. Full-thickness defects Full-thickness nasal defects are in three types: (i) wounds to the skin and to the soft tissues, featuring either exposed bone or exposed cartilage, or both; (ii) wounds extending through the nasal skeleton; and (iii) wounds traversing all three nasal layers: skin, muscle, and the osseo-cartilaginous framework. Based upon the dimensions (length, width, depth) and topographic locale of the wound and the number of missing nasal-tissue layers, the surgeon determines the rhinoplastic technique for correcting a full-thickness defect; each of the aesthetic nasal subunits is considered separately and in combination.
== Advertising == A&W does not do national advertising; the primary factor for such being the lack of restaurants in certain parts of the United States. Its first attempt at doing a national television commercial was on June 16, 1969, when it booked for a slot on NBC's Monday Night at the Movies to advertise take-home gallons of root beer. In 1976, A&W Restaurants participated in the Easter Seals Telethon, where money from large root beer mugs was collected by the local restaurant on behalf of the TV station broadcasting the telethon in the area. In 1997, the chain adopted All American Food as its slogan in order to achieve widespread brand recognition. The chain increased its marketing budget in February 2000, eyeing for a new line of burgers in January 2001. For the summer of 2007, the chain launched the Moove to American campaign, which was created to counter competing chains relying exclusively on foreign beef; the campaign started on June 28 with a stunt featuring 35 cows sent on a barge to the Statue of Liberty. The aim was to petition the National Cattlemen's Beef Association to support consumption of U.S. beef. There was also a campaign to set up a new custom burger, with the winner heading over to Louisville to work for its serving in restaurants. A grassroots partnership with Green Bay Packers receiver Greg Jennings began in 2009, where Papa Burgers were sold at a price of 85 cents in Green Bay restaurants if Jennings made a touchdown. Due to its success, the campaign expanded to include all of Wisconsin in 2010.
Sources: en.wikipedia.org
=== Adelaide Crows–Kurt Tippett contract scandal === During the trade period leading up to the 2013 season, Adelaide Crows forward Kurt Tippett sought to be traded. During trade negotiations, information was uncovered which brought into question the legality under AFL rules of Tippett's 2009 contract extension with Adelaide. The AFL investigated Tippett's contract during October and November, and charged Tippett and Adelaide with a total of eleven charges relating to draft tampering and breaching the total player payments, including:
=== Pain in mammals === In mutant yellow-orange mice and human redheads, both with nonfunctional MC1R, both genotypes display reduced sensitivity to noxious stimuli and increased analgesic responsiveness to morphine-metabolite analgesics. These observations suggest a role for mammalian MC1R outside the pigment cell, though the exact mechanism through which the protein can modulate pain sensation is not known. In a certain genetic background in mice it has been reported that animals lacking MC1R had increased tolerance to capsaicin acting through the TRPV1 receptor and decreased response to chemically induced inflammatory pain. Humans with MC1R mutations have been reported to need approximately 20% more inhalational anaesthetic than controls. Lidocaine was reported to be much less effective in reducing pain in another study of humans with MC1R mutations
=== ZMAb === ZMAb is a mixture of three mouse mAbs: m1H3, m2G4, and m4G7. A study published in November 2013 found that EBOV-infected macaque monkeys survived after being given a therapy with a combination of three EBOV surface glycoprotein (EBOV-GP)-specific monoclonal antibodies (ZMAb) within 24 hours of infection. The authors concluded that post-exposure treatment resulted in a robust immune response, with good protection for up to 10 weeks and some protection at 13 weeks. ZMab was created by the NML and licensed to Defyrus, a Toronto-based biodefense company, with further funding by the Public Health Agency of Canada.
== Formulations == The term dosage form may also sometimes refer only to the pharmaceutical formulation of a drug product's constituent substances, without considering its final configuration as a consumable product (e.g., capsule, patch, etc.). Due to the somewhat ambiguous nature and overlap of these terms within the pharmaceutical industry, caution is advisable when discussing them with others who may interpret the terminology differently.
Sources: en.wikipedia.org
== Pharmacokinetics == After intravenous administration in humans, methylene blue shows a multiphasic change in concentration, with a terminal half-life of 5.25 hours. The initial disappearance from blood actually reflects its movement into organs, with brain, liver, and bile all showing significantly higher concentrations than blood in rats. The overall area under the curve in oral (dry gelatin capsule) administration is only 6.5% of the AUC for IV administration; judging from rat studies, the significantly altered organ distribution plays a key role in this difference. Administration as an oral solution (500 mg in 200 mL) greatly increases the bioavailability to 72.3±23.9%. In this newer study, the terminal half-lives were reported as 18.5±11.8 hours for IV use and 18.3±7.2 hours for oral use. The tmax for oral use is 2.2 hours, compared to 0.5 hours for iv use.
== Other epitope-tag combinations == The principle of tandem-affinity purification of multiprotein complexes is not limited to the combination of CBP and Protein A tags used in the original work by Rigaut et al. (1999). For example, the combination of FLAG- and HA-tags has been used since 2000 by the group of Nakatani to purify numerous protein complexes from mammalian cells. Many other tag combinations have been proposed since the TAP principle was published.
== Areas of application and limits == First used in theoretical physics, the molecular dynamics method gained popularity in materials science soon afterward, and since the 1970s it has also been commonly used in biochemistry and biophysics. MD is frequently used to refine 3-dimensional structures of proteins and other macromolecules based on experimental constraints from X-ray crystallography or NMR spectroscopy. In physics, MD is used to examine the dynamics of atomic-level phenomena that cannot be observed directly, such as thin film growth and ion subplantation, and to examine the physical properties of nanotechnological devices that have not or cannot yet be created. In biophysics and structural biology, the method is frequently applied to study the motions of macromolecules such as proteins and nucleic acids, which can be useful for interpreting the results of certain biophysical experiments and for modeling interactions with other molecules, as in ligand docking. In principle, MD can be used for ab initio prediction of protein structure by simulating folding of the polypeptide chain from a random coil. MD can also be used to compute other thermodynamic properties such as drug solubilities and free energies of solvation including in polymers. The results of MD simulations can be tested through comparison to experiments that measure molecular dynamics, of which a popular method is NMR spectroscopy.
=== Industrial discharge === Industrial discharge is when waste products are released into the environment from manufacturing and chemical processing facilities. This waste can include a wide variety of CEC like heavy metals, solvents, and various organic compounds that are not regularly detected for or removed by standard treatment processes. These contaminants can accumulate in sediments and biota, posing risks to aquatic life and human health. The complexity and diversity of industrial discharge requires advanced treatment technologies and stricter regulatory frameworks to prevent CEC from contaminating the environment. Advanced oxidation processes and membrane technologies have been researched and shown to reduce CEC from industrial discharge, however there is an excessive cost to retrofit existing treatment facilities with this technology.
Selenols (R−SeH) are the selenium equivalents of alcohols and thiols. relatively unstable and generally have an unpleasant smell. Benzeneselenol (also called selenophenol or PhSeH) is more acidic (pKa 5.9) than thiophenol (pKa 6.5) and also oxidizes more readily to the diselenide. Indeed, selenophenol is prepared by reduction of diphenyldiselenide as the former is not air-stable. Diselenides (R−Se−Se−R) are the selenium equivalents of peroxides and disulfides. They are useful shelf-stable precursors to more reactive organoselenium reagents such as selenols and selanyl halides. Diselenides are typically prepared from the autoxidation of selenolates or alkylation of the diselenide anion, but secondary diselenides can be produced from the hydrogen selenide reduction of ketones. Best known in organic chemistry is diphenyldiselenide, prepared from phenylmagnesium bromide and selenium followed by aerobic oxidation of the product PhSeMgBr. Heating decomposes them to selenoethers or (in rare cases) the coupled alkane. Selanyl halides (R−Se−Cl, R−Se−Br) are prepared by halogenation of diselenides. For example, bromination of diphenyldiselenide gives phenylselanyl bromide (PhSeBr). These compounds are Lewis acidic, often stabilized by intramolecular coordination, and sources of "PhSe+". Excess halogen gives the corresponding trihalides. Selenides (R−Se−R), also called selenoethers, are the selenium equivalents of ethers and sulfides. One example is dimethylselenide ((CH3)2Se). These are the most prevalent organoselenium compounds.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.